202 related articles for article (PubMed ID: 34093830)
1. Systematic Analysis of 4-gene Prognostic Signature in Patients with Diffuse Gliomas Based on Gene Expression Profiles.
Huang C; Xiong Z; Yang Q; Li X
J Cancer; 2021; 12(14):4295-4306. PubMed ID: 34093830
[No Abstract] [Full Text] [Related]
2. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
3. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
4. Identification of RNA: 5-Methylcytosine Methyltransferases-Related Signature for Predicting Prognosis in Glioma.
Wang P; Wu M; Tu Z; Tao C; Hu Q; Li K; Zhu X; Huang K
Front Oncol; 2020; 10():1119. PubMed ID: 32974125
[No Abstract] [Full Text] [Related]
5. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of multi-omics data of recurrent gliomas identifies a recurrence-related signature as a novel prognostic marker.
Wang QW; Zhao Z; Bao ZS; Jiang T; Zhu YJ
Am J Cancer Res; 2021; 11(4):1226-1246. PubMed ID: 33948355
[TBL] [Abstract][Full Text] [Related]
7. Identification of potential biomarkers related to glioma survival by gene expression profile analysis.
Hsu JB; Chang TH; Lee GA; Lee TY; Chen CY
BMC Med Genomics; 2019 Mar; 11(Suppl 7):34. PubMed ID: 30894197
[TBL] [Abstract][Full Text] [Related]
8. Integrative Analysis of DNA Methylation and Gene Expression Identify a Three-Gene Signature for Predicting Prognosis in Lower-Grade Gliomas.
Zeng WJ; Yang YL; Liu ZZ; Wen ZP; Chen YH; Hu XL; Cheng Q; Xiao J; Zhao J; Chen XP
Cell Physiol Biochem; 2018; 47(1):428-439. PubMed ID: 29794476
[TBL] [Abstract][Full Text] [Related]
9. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
[TBL] [Abstract][Full Text] [Related]
10. Identification of a Prognostic Hypoxia-Associated Gene Set in IDH-Mutant Glioma.
Dao Trong P; Rösch S; Mairbäurl H; Pusch S; Unterberg A; Herold-Mende C; Warta R
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257451
[TBL] [Abstract][Full Text] [Related]
11. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
Paul Y; Mondal B; Patil V; Somasundaram K
Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
[TBL] [Abstract][Full Text] [Related]
12. Omics-based integrated analysis identified ATRX as a biomarker associated with glioma diagnosis and prognosis.
Xie Y; Tan Y; Yang C; Zhang X; Xu C; Qiao X; Xu J; Tian S; Fang C; Kang C
Cancer Biol Med; 2019 Nov; 16(4):784-796. PubMed ID: 31908895
[TBL] [Abstract][Full Text] [Related]
13. Development and Validation of an IDH1-Associated Immune Prognostic Signature for Diffuse Lower-Grade Glioma.
Deng X; Lin D; Chen B; Zhang X; Xu X; Yang Z; Shen X; Yang L; Lu X; Sheng H; Yin B; Zhang N; Lin J
Front Oncol; 2019; 9():1310. PubMed ID: 31824866
[TBL] [Abstract][Full Text] [Related]
14. Isocitrate dehydrogenase 1-mutated human gliomas depend on lactate and glutamate to alleviate metabolic stress.
Lenting K; Khurshed M; Peeters TH; van den Heuvel CNAM; van Lith SAM; de Bitter T; Hendriks W; Span PN; Molenaar RJ; Botman D; Verrijp K; Heerschap A; Ter Laan M; Kusters B; van Ewijk A; Huynen MA; van Noorden CJF; Leenders WPJ
FASEB J; 2019 Jan; 33(1):557-571. PubMed ID: 30001166
[TBL] [Abstract][Full Text] [Related]
15. TMEFF2 promoter hypermethylation is an unfavorable prognostic marker in gliomas.
Xie S; Zhang Y; Peng T; Guo J; Cao Y; Guo J; Shi X; Li Y; Liu Y; Qi S; Wang H
Cancer Cell Int; 2021 Mar; 21(1):148. PubMed ID: 33663520
[TBL] [Abstract][Full Text] [Related]
16. Prognosis Analysis and Validation of m
Lin S; Xu H; Zhang A; Ni Y; Xu Y; Meng T; Wang M; Lou M
Front Oncol; 2020; 10():541401. PubMed ID: 33123464
[TBL] [Abstract][Full Text] [Related]
17. Molecular Diagnosis of Diffuse Gliomas through Sequencing of Cell-Free Circulating Tumor DNA from Cerebrospinal Fluid.
Martínez-Ricarte F; Mayor R; Martínez-Sáez E; Rubio-Pérez C; Pineda E; Cordero E; Cicuéndez M; Poca MA; López-Bigas N; Ramon Y Cajal S; Vieito M; Carles J; Tabernero J; Vivancos A; Gallego S; Graus F; Sahuquillo J; Seoane J
Clin Cancer Res; 2018 Jun; 24(12):2812-2819. PubMed ID: 29615461
[No Abstract] [Full Text] [Related]
18. Three Immune-Associated Subtypes of Diffuse Glioma Differ in Immune Infiltration, Immune Checkpoint Molecules, and Prognosis.
Zhou Q; Yan X; Liu W; Yin W; Xu H; Cheng D; Jiang X; Ren C
Front Oncol; 2020; 10():586019. PubMed ID: 33425739
[TBL] [Abstract][Full Text] [Related]
19. Identification of a five B cell-associated gene prognostic and predictive signature for advanced glioma patients harboring immunosuppressive subtype preference.
Zhang C; Li J; Wang H; Song SW
Oncotarget; 2016 Nov; 7(45):73971-73983. PubMed ID: 27738332
[TBL] [Abstract][Full Text] [Related]
20. Contrast enhancement predicting survival in integrated molecular subtypes of diffuse glioma: an observational cohort study.
Hempel JM; Brendle C; Bender B; Bier G; Skardelly M; Gepfner-Tuma I; Eckert F; Ernemann U; Schittenhelm J
J Neurooncol; 2018 Sep; 139(2):373-381. PubMed ID: 29667086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
